Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992681 | 0.86 | CA12 (0.46) | CA12CA1CA9PREPAHR | |
| SCHEMBL24455832 | 0.81 | CA12 (0.45) | CA12CA1CA9PREPMEN1 | |
| SCHEMBL29653234 | 0.81 | CA12 (0.45) | CA12CA1CA9PREPMEN1 | |
| SCHEMBL20535255 | 0.81 | CA12 (0.45) | CA12CA1CA9PREPHSP90AB1 | |
| SCHEMBL3690504 | 0.80 | CA12 (0.47) | CA12CA1CA9PREPCHRNA3 | |
| SCHEMBL1828057 | 0.80 | CA12 (0.47) | CA12CA1CA9PREPHSP90AB1 | |
| SCHEMBL7045640 | 0.79 | CA12 (0.46) | CA12CA1CA9PREPMEN1 | |
| SCHEMBL22128458 | 0.79 | CA12 (0.46) | CA12CA1CA9PREPHSP90AB1 | |
| SCHEMBL28422272 | 0.79 | CA12 (0.46) | CA12CA1CA9PREPMCHR1 | |
| SCHEMBL2114690 | 0.78 | CA12 (0.43) | CA12CA1CA9PREPHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4691553-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4534536-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-23 | — | — | US | disclosed |
| CN-113302190-B | FXR (NR 1H 4) modulating compounds | 吉利德科学公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240335442-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) | 2024-10-10 | — | — | US | disclosed |
| EP-4089072-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4382100-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118076348-A | N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same | 欧罗法玛实验室股份公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| EP-3233831-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170298068-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-19 | — | — | US | disclosed |
| WO-2017128896-A1 | FXR AGONIST AND PREPARATION METHOD AND USE THEREOF | 江苏豪森药业集团有限公司 | 2017-08-03 | — | — | WO | disclosed |
| WO-2016096116-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096116-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| EP-3034499-A1 | Novel FXR (NR1H4) modulating compounds | Gilead Sciences, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | CA12 4742/4885CA1 4536/4885CA9 4854/4885 |
| US-20170298068-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | CA12 4698/4885CA1 4488/4885CA9 4843/4885 |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | CA12 4661/4885CA1 4307/4885CA9 4851/4885 |
| US-20240335442-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | SCN1A, SCN7A, SCN8A | CA12 2541/4885CA1 699/4885CA9 1184/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | CA12 4661/4885CA1 4307/4885CA9 4851/4885 |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | CA12 4265/4885CA1 3288/4885CA9 4154/4885 |
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | CA12 4661/4885CA1 4307/4885CA9 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.